[MRK] MRK Dividend Analysis: Is Merck & Co., Inc. a Buy Now?
[ANALYSIS NOTE] Our latest MRK Dividend Analysis suggests that Merck & Co., Inc. (MRK) continues to be a high-conviction play for income-oriented investors. As a Wall Street analyst monitoring the healthcare sector, I observe that Merck’s robust pipeline and market-leading positions in oncology and immunology provide a durable foundation for its capital return program. This … Read more